News: Teva Pharmaceutical Industries Ltd (TEVA.N)
5 Mar 2015
Wed, Mar 4 2015
March 4 - * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and
- The top U.S. patent appeals court has affirmed a district court decision allowing generic drugmaker Lupin Ltd, but not Teva Pharmaceuticals, to make generic versions of ViiV Healthcare Co's HIV drugs.
- Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.
Feb 11 - Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.
TEL AVIV - Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive.
* Teva seeks growth markets, complex generics, specialty drugs
* There might not be any generic Copaxone competition in 2015 but we assume there may be -CEO Further company coverage: (Reporting By Steven Scheer)
* Plans 7 drug launches in 2015 with $400 million of new revenue -CEO Further company coverage: (Reporting By Tova Cohen)
TEL AVIV, Feb 5 - Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year.
- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.
- DURECT's Endogenous Epigenomic Regulator DUR-928 - What You Need To Know
- 10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
- Week In Review: Eddingpharm Pays $169 Million For China Rights To Omega-3 Drug
- Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
- A Quick Review Of The Asthma Market
- The Passive DGI Portfolio: Portfolio Update #3
- Teva to Present at the Barclays Global Healthcare Conference
- Teva Announces Sale of Sellersville, PA Facility
- Teva Announces Early Results of Debt Tender Offer, Pricing, Election of Early Settlement and Increase in Maximum Amount and Priority 2 Notes Tender Cap
- Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed
- Teva to Present at the Cowen & Company 35th Annual Healthcare Conference
- The Lancet Respiratory Medicine and AAAAI Publish Positive Data from Phase III Trials of Teva’s Reslizumab for the Treatment of Moderate to Severe Asthma in Patients with Elevated Blood Eosinophils
- Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Teva Pharmaceutical Industries Ltd. Stockholders
- Teva Bolsters Injectable Portfolio with Launch of Generic Lovenox® and Generic Zyvox® in the United States
- Teva and Eagle Pharmaceuticals Announce Teva’s License to Commercialize Eagle’s Bendamustine Rapid Infusion Product